88 related articles for article (PubMed ID: 38698850)
1. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Lê H; Deforges J; Cutolo P; Lamarque A; Hua G; Lindner V; Jain S; Balloul JM; Benkirane-Jessel N; Quéméneur E
Front Immunol; 2024; 15():1379613. PubMed ID: 38698850
[TBL] [Abstract][Full Text] [Related]
3. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for thoracic oncology gone viral.
Patel MR
Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
[TBL] [Abstract][Full Text] [Related]
5. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
7. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
8.
Lê H; Deforges J; Hua G; Idoux-Gillet Y; Ponté C; Lindner V; Olland A; Falcoz PE; Zaupa C; Jain S; Quéméneur E; Benkirane-Jessel N; Balloul JM
iScience; 2023 Oct; 26(10):108094. PubMed ID: 37860774
[TBL] [Abstract][Full Text] [Related]
9. Organotypic Models for Functional Drug Testing of Human Cancers.
Huang YL; Dickerson LK; Kenerson H; Jiang X; Pillarisetty V; Tian Q; Hood L; Gujral TS; Yeung RS
BME Front; 2023; 4():0022. PubMed ID: 37849667
[TBL] [Abstract][Full Text] [Related]
10. Hot and cold tumors: Immunological features and the therapeutic strategies.
Wang L; Geng H; Liu Y; Liu L; Chen Y; Wu F; Liu Z; Ling S; Wang Y; Zhou L
MedComm (2020); 2023 Oct; 4(5):e343. PubMed ID: 37638340
[TBL] [Abstract][Full Text] [Related]
11. Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.
Alessi JV; Ricciuti B; Wang X; Pecci F; Di Federico A; Lamberti G; Elkrief A; Rodig SJ; Lebow ES; Eicholz JE; Thor M; Rimner A; Schoenfeld AJ; Chaft JE; Johnson BE; Gomez DR; Awad MM; Shaverdian N
Nat Commun; 2023 Jul; 14(1):4238. PubMed ID: 37454214
[TBL] [Abstract][Full Text] [Related]
12. Human disease models in drug development.
Loewa A; Feng JJ; Hedtrich S
Nat Rev Bioeng; 2023 May; ():1-15. PubMed ID: 37359774
[TBL] [Abstract][Full Text] [Related]
13. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
[TBL] [Abstract][Full Text] [Related]
14. GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC.
Fan H; Shi Y; Wang H; Li Y; Mei J; Xu J; Liu C
Int J Gen Med; 2023; 16():1757-1769. PubMed ID: 37193249
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
